SSB, Novasep to Develop Membrane Chromatography Systems

Published on: 

Sartorius Stedim Biotech (SSB) and Novasep will partner to develop systems for membrane chromatography using Novasep’s BioSC platform and SSB’s single-use technology.

On March 5, 2019, Sartorius Stedim Biotech (SSB), a biopharmaceutical supplier, and Novasep, a provider of molecule production and purification services, have entered into a collaboration agreement in which the companies will develop membrane chromatography systems using Novasep’s BioSC platform and SSB’s single-use technology.

According to SSB, systems that are currently on the market are designed for resins, but do not take full advantage of membrane chromatography capabilities. Optimally run membrane chromatography processes will provide an efficient alternative to batch and continuous resin-based chromatography, resulting in higher productivity, smaller scale operations, and increased robustness, SBB reports.

Novasep specializes in the design, manufacture and control of resin-based batch and continuous chromatography systems. The company’s BioSc platform is a low-pressure continuous chromatography solution for the purification of monoclonal antibodies, blood fractions and other biologics. The platform is adaptable, with operations from one column up to six columns in batch, parallel batch, continuous chromatography, or continuous process. Novasep states that the platform can easily switch from batch to continuous, has a reduction of resin and buffer by up to 75%, and increased productivity by two- to six-fold.


Source: Sartorius Stedim Biotech, Novasep